Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
|Articles|July 1, 2002
Men with low PSA may not need annual screening
Orlando, FL-A new analysis of data from the National Cancer Institute'snationwide Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screeningtrial suggests that annual PSA screening may not be necessary for many men.
Advertisement
Advertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
4
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
5